Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice

Anti-Cancer Drugs

Volumn 17, Issue 3, 2006, Pages 333-336

  Fichtner, Iduna ^a   Pampillón, Clara ^b   Sweeney, Nigel J ^b   Strohfeldt, Katja ^b   Tacke, Matthias ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Anti cancer drug; Caki 1; Cisplatin; Renal cell cancer; Titanocene

Indexed keywords

BIS [(4 METHOXYBENZYL)CYCLOPENTADIENYL]TITANIUM; CISPLATIN; TITANOCENE; TITANOCENE Y; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAKI 1 CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY METASTASIS; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; ORGANOMETALLIC COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646089648     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200603000-00012     Document Type: Article

References (28)

1. Gelasco A, Lippard SJ. Anticancer activity of cisplatin and related complexes. Top Biol Inorg Chem 1999; 1:1-43.
2. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99:2467-2498.
3. Farrell N, Qu Y, Roberts JD. Chemistry and biology of multifunctional DNA binding agents. Top Biol Inorg Chem 1999; 1:99-115.
4. Köpf-Maier P, Köpf H. Non-platinum group metal antitumor agents. History, current status, and perspectives. Chem Rev 1987; 87:1137-1152.
5. Köpf-Maier P, Köpf H. Transition and main-group metal cyclopentadienyl complexes: preclinical studies on a series of antitumor agents of different structural type. Struct Bonding 1988; 70:103-194.
6. Lummen G, Sperling H, Luboldt H, Otto T, Rubben H. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 1998; 42:415-417.
7. Kröger N, Kleeberg UR, Mross KB, Edler L, Saß G, Hossfeld DK. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie 2000; 23:60-62.
8. 2 and implications for anticancer activity. Metal-Based Drugs 1998; 5:207-215.
9. Allen OR, Croll L, Gott AL, Knox RJ, McGowan PC. Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs. Organometallics 2004; 23:288-292.
10. Boyles JR, Baird MC, Campling BG, Jain N. Enhanced anti-cancer activities of some derivatives of titanocene dichloride. J Inorg Biochem 2001; 84:159-162.
11. Causey PW, Baird MC. Synthesis, characterization, and assessment of cytotoxic properties of a series of titanocene dichloride derivatives. Organometallics 2004; 23:4486-4494.
12. Meyer R, Brink S, van Rensburg CEJ, Joone GK, Görls H, Lotz S. Synthesis, characterization and antitumor properties of titanocene derivatives with thiophene containing ligands. J Organomet Chem 2005; 690: 117-125.
13. 2). J Organomet Chem 1997; 545-546:105-110.
14. Hartl F, Cuffe L, Dunne JP, Fox S, Mahabiersing T, Tacke M. Reduction of substituted fulvenes studied by spectro-electrochemistry and ab initio theory. J Mol Struct 2001; 559:331-339.
15. 5. J Mol Struct 2001; 570:197-202.
16. Fox S, Dunne JP, Dronskowski D, Schmitz D, Tacke M. Synthesis and structural characterisation of a novel chiral ansa-cobaltocenium hexafluorophospate. Eur J Inorg Chem 2002; 3039-3046.
17. Eisch JJ, Xian S, Owuor FA. Novel synthesis of ansa-metallocenes via the reductive dimerization of fulvenes with group 4 metal divalent halides. Organometallics 1998; 17:5219-5221.
18. Eisch JJ, Owuor FA, Xian S. Novel synthesis of unbridged, sterically substituted zirconocene dichlorides from fulvenes and dialkylzirconium dichlorides via zirconium(IV) hydride transfer. Organometallics 1999; 18:1583-1585.
19. 2. Organometallics 1997; 16:4567-4571.
20. Fox S, Dunne JP, Tacke M, Gallagher JF. Novel derivatives of ansa-titanocenes procured from 6-phenylfulvene: a combined experimental and theoretical study. Inorganica Chim Acta 2004; 357:225-234.
21. Tacke M, Allen LT, Cuffe LP, Gallagher WM, Lou Y, Mendoza O, et al. Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. J Organomet Chem 2004; 689:2242-2249.
22. Rehmann FJK, Cuffe LP, Mendoza O, Rai DK, Sweeney N, Strohfeldt K, et al. Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Appl Organomet Chem 2005; 19:293-300.
23. Tacke M, Cuffe LP, Gallagher WM, Lou Y, Mendoza O, Müller-Bunz H, et al. Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride. J Inorg Biochem 2004; 98:1987-1994.
24. Rehmann FJK, Rous AJ, Mendoza O, Pampillon C, Strohfeldt K, Sweeney N, et al. Novel substituted ansa-titanocene anti-cancer drugs. Polyhedron 2005; 24:1250-1255.
25. Sweeney N, Mendoza O, Müller-Bunz H, Pampillón C, Rehmann F-JK, Strohfeldt K, et al. Novel benzyl substituted titanocene anti-cancer drugs. J Organomet Chem 2005; 690:4537-4544.
26. Kelter G, Sweeney N, Strohfeldt K, Fiebig H-H, Tacke M. In vitro anti-tumor activity of bridged and unbridged benzyl-substituted titanocenes. Anticancer Drugs 2005; 16:1091-1098.
27. Oberschmidt O, Hanauske AR, Rehmann F-JK, Strohfeldt K, Sweeney N, Tacke M. Preclinical activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony forming units. Anticancer Drugs 2005; 16:1071-1073.
28. Stein U, Walther W, Lemm M, Naundorf H, Fichtner I. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer 1997; 72: 885-891.